CVRx to Present at the Canaccord Genuity 44th Annual Growth Conference
Rhea-AI Summary
CVRx, a commercial-stage medical device company, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's management team is set to present on Wednesday, August 14, 2024, at 12:30 PM Eastern Time. This presentation will be accessible to investors and interested parties through a live audio webcast on the investor relations page of CVRx's official website.
This event provides an opportunity for CVRx to showcase its progress and future plans to a wide audience of investors and industry professionals. The company's participation in such a prominent conference may indicate its commitment to transparency and engagement with the investment community.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CVRX declined 2.92%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MINNEAPOLIS, July 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024. The Company is scheduled to present at 12:30 PM Eastern Time the same day via webcast.
A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com.
About CVRx, Inc.
CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com
Media Contact:
Laura O’Neill
Finn Partners
402-499-8203
laura.oneill@finnpartners.com
FAQ
When is CVRx presenting at the Canaccord Genuity 44th Annual Growth Conference?
How can investors access CVRx's presentation at the Canaccord Genuity conference?
What is the stock symbol for CVRx?
What type of company is CVRx?
